Literature DB >> 10831323

A native soluble form of CTLA-4.

M K Oaks1, K M Hallett, R T Penwell, E C Stauber, S J Warren, A J Tector.   

Abstract

CTLA-4 is an immunoregulatory receptor expressed on the surface of activated T and B lymphocytes. The counterreceptors for CTLA-4 are the B7 family molecules. We describe alternatively spliced mRNAs expressed in hematolymphoid tissues of humans, mice, and rats that lack the transmembrane domain coded by exon 3 of the CTLA-4 gene. These alternate transcripts were detected by RT-PCR in B cells and resting T cells of both the CD4 and the CD8 phenotype. Activation of human blood mononuclear cells with PHA or anti-CD3 + anti-CD28 monoclonal antibodies appears to effect a decrease in the amount of the alternative transcript relative to the full-length transcript. Recombinant sCTLA-4 is a B7-binding protein and has immunomodulatory effects as measured by inhibition of the mixed leukocyte response. Human serum contains immunoreactive material consistent with a native soluble form of CTLA-4. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831323     DOI: 10.1006/cimm.2000.1649

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  62 in total

1.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

4.  Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy.

Authors:  C K Wong; Amy W Y Ho; Peter C Y Tong; C Y Yeung; Juliana C N Chan; Alice P S Kong; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

Review 5.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

6.  Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation.

Authors:  O Tapirdamaz; V Pravica; H J Metselaar; B Hansen; L Moons; J B J van Meurs; I V Hutchinson; J Shaw; K Agarwal; D H Adams; C P Day; J Kwekkeboom
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

Review 7.  Soluble immune checkpoints in cancer: production, function and biological significance.

Authors:  Daqian Gu; Xiang Ao; Yu Yang; Zhuo Chen; Xiang Xu
Journal:  J Immunother Cancer       Date:  2018-11-27       Impact factor: 13.751

Review 8.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.

Authors:  Eric Toussirot; Philippe Saas; Marina Deschamps; Fabienne Pouthier; Lucille Perrot; Sylvain Perruche; Jacqueline Chabod; Pierre Tiberghien; Daniel Wendling
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

10.  Biochemical analysis of CTLA-4 immunoreactive material from human blood.

Authors:  Matt Tector; Bhupendra O Khatri; Karen Kozinski; Kate Dennert; Martin K Oaks
Journal:  BMC Immunol       Date:  2009-09-22       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.